Apyx Medical (NASDAQ: APYX) files 8-K on Q4 and 2025 revenue
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Apyx Medical Corporation reported that it has released preliminary revenue results for the fourth quarter and full year ended December 31, 2025. The company disclosed this information through a press release dated January 12, 2026, which is furnished as Exhibit 99.1. The report clarifies that these disclosures are provided under a results of operations and financial condition item and are furnished rather than filed under securities laws, which affects how they are treated for liability purposes.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices, zip code)
(727 ) 384-2323
(Issuer's telephone number)
_____________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition
On January 12, 2026, Apyx Medical Corporation (the “Company”) issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2025.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Press release dated January 12, 2026
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: January 12, 2026
|
Apyx Medical Corporation
|
||
|
By:
|
/s/ Matthew Hill
|
||
|
Matthew Hill
|
|||
|
Chief Financial Officer, Secretary and Treasurer
|
|||
FAQ
What did Apyx Medical (APYX) disclose in this 8-K filing?
Apyx Medical reported that it issued a press release with preliminary revenue results for the fourth quarter and year ended December 31, 2025, and furnished that release as an exhibit.
Which period do the preliminary results cover for Apyx Medical (APYX)?
The preliminary revenue results cover the fourth quarter and the full fiscal year ended December 31, 2025.
Where can investors find the detailed preliminary revenue figures for APYX?
The detailed preliminary revenue figures are contained in the press release furnished as Exhibit 99.1, dated January 12, 2026.
Is the Apyx Medical (APYX) revenue information considered filed with the SEC?
No. The company states that the information in this report, including Exhibit 99.1, is being furnished under the results of operations item and is not deemed filed for purposes of Section 18 of the Exchange Act.
Who signed the Apyx Medical (APYX) current report?
The report was signed on behalf of Apyx Medical Corporation by Matthew Hill, who serves as Chief Financial Officer, Secretary and Treasurer.
What exhibits are included with this Apyx Medical (APYX) 8-K?
The filing includes Exhibit 99.1, a press release dated January 12, 2026, and a cover page interactive data file identified as Exhibit 104.